Federal Funding and Clinical Trial Sponsorship in Pancreatic Cancer From 2003 to 2022

Document Type : Short Communication

Authors

1 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, USA

2 Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Abstract

Pancreatic cancer remains one of the deadliest malignancies, with a persistently low five-year survival rate. The Recalcitrant Cancer Research Act (RCRA) of 2012 is one example of legislation aimed at accelerating research in highmortality cancers. This study examines long-term trends in federal funding and clinical trial sponsorship for pancreatic cancer over a 20-year period, spanning before and after the RCRA. We conducted a retrospective analysis of National Cancer Institute (NCI) funding data and pancreatic cancer clinical trials registered on ClinicalTrials.gov between 2003 and 2022. Linear regression with pre- and post-2013 comparisons evaluated changes over time. NCI support for pancreatic cancer increased 3.5-fold – from $78 million in 2003 to $250 million in 2022 (inflation-adjusted). The annual growth rate rose from $7.4 million per year before 2013 to $12.2 million per year after 2013. The share of the NCI’s budget allocated to pancreatic cancer also rose from 0.9% to 3.4%, with no significant shift in slope after 2013 (P = .98). Federally-funded clinical trials declined sharply before 2013, decreasing by 2.8% per year, and then stabilized after 2013, with a nonsignificant slope of –0.95% per year (interaction P = .06). Meanwhile, industry-sponsored trials grew substantially, increasing from 30% to nearly 75%, increasing by 2.0% per year after 2013. Findings were consistent in logistic regression models. These findings suggest that while federal investment in pancreatic cancer research has grown, the expansion of clinical trials has been driven largely by industry, suggesting that federal investment has likely been directed toward foundational and preclinical research. Strengthening public-private collaboration and maintaining federal engagement will be critical to ensuring that research advances align with patient-centered goals.

Keywords

References

  1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:3322/caac.21820
  2. Haghighat S, Jiang C, El-Rifai W, Zaika A, Goldberg DS, Kumar S. Urgent need to mitigate disparities in federal funding for cancer research. J Natl Cancer Inst. 2023;115(10):1220-1223. doi:1093/jnci/djad097
  3. Hall BR, Cannon A, Atri P, et al. A comparative analysis of survival and funding discrepancies in cancers with high mortality. Ann Surg. 2020;271(2):296-302. doi:1097/SLA.0000000000003042
  4. Siena LM, Papamanolis L, Siebert MJ, Bellomo RK, Ioannidis JPA. Industry involvement and transparency in the most cited clinical trials, 2019-2022. JAMA Netw Open. 2023;6(11):e2343425. doi:1001/jamanetworkopen.2023.43425
  5. Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health funding for clinical trials registered in ClinicalTrials.gov. JAMA.  2015;314(23):2566-2567. doi:10.1001/jama.2015.12206
  6. Gresham GK, Ehrhardt S, Meinert JL, Appel LJ, Meinert CL. Characteristics and trends of clinical trials funded by the National Institutes of Health between 2005 and 2015. Clin Trials. 2018;15(1):65-74. doi:1177/1740774517727742
  7. Chakraborty N, Brown M, Persaud S, et al. Trends in financial payments from industry to US cancer centers, 2014-2021. JNCI Cancer Spectr. 2024;8(3):pkae015. doi:1093/jncics/pkae015
International Journal of Health Policy and Management
Volume 15, Issue 1
2026
Pages 1-5

Files

History

  • Received Date: 01 June 2025
  • Revised Date: 30 November 2025
  • Accepted Date: 04 March 2026
  • First Published Date: 10 March 2026
  • Published Date: 01 December 2026

Share

How to cite

Statistics